Back

Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris

Carter, G. P.; McKay, Z. P.; Katz, M. A.; Disla, L.; Nardone, D.; Southwell, D. G.; Brown, M. C.; Gromeier, M.

2026-04-08 neuroscience
10.64898/2026.04.06.716590 bioRxiv
Show abstract

Owing to pivotal roles in CNS debris clearance and homeostasis, microglia are central targets for the therapy of neurodegenerative diseases. Intricate proximity to neurons, the inherent danger of neuroimmune toxicity, and intrinsically high plasticity and adaptability, impose high hurdles on microglia modulation. Attenuated viruses are being tested extensively against CNS malignancies (i.e., cancer virotherapy); yet, aside from viral vector-mediated payload delivery, virotherapy for non-neoplastic CNS disease remains unexplored. Here we report disseminated targeting of microglia with the highly attenuated polio:rhinovirus chimera, PVSRIPO, that culminated in profound, durable microglia reprogramming. This phenotype, rooted in extended cytoplasmic viral (v)RNA replication, was non-cytopathogenic and did not yield virus progeny or dissemination. vRNA replication in microglia triggered selective interferon (IFN) regulatory factor (IRF) 3/IRF7 transcriptional programs in the relative absence of NF{kappa}B-driven proinflammatory cytokine responses and elicited robust phagocytosis of both tumor cells and amyloid-beta. Targeting of microglia with PVSRIPO mediated immunotherapy in a mouse glioma model and the clearance of oligomeric amyloid-beta deposits in an injectable model of neurotoxic amyloid accumulation. This work identifies attenuated virotherapy as an approach to safely and effectively invigorate microglia function in immune surveillance and neurotoxic debris clearance.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
71 papers in training set
Top 0.1%
18.7%
2
Nature Communications
4913 papers in training set
Top 9%
14.7%
3
Nature Biotechnology
147 papers in training set
Top 1%
6.8%
4
Cell Reports Medicine
140 papers in training set
Top 0.7%
4.9%
5
EMBO Molecular Medicine
85 papers in training set
Top 0.3%
4.3%
6
Advanced Science
249 papers in training set
Top 4%
4.3%
50% of probability mass above
7
Science Translational Medicine
111 papers in training set
Top 1%
2.6%
8
Science Advances
1098 papers in training set
Top 10%
2.6%
9
Cell Reports
1338 papers in training set
Top 19%
2.5%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 26%
2.5%
11
Nature Neuroscience
216 papers in training set
Top 4%
1.7%
12
Cell
370 papers in training set
Top 11%
1.7%
13
Immunity
58 papers in training set
Top 3%
1.5%
14
Nature Biomedical Engineering
42 papers in training set
Top 1%
1.3%
15
Neuron
282 papers in training set
Top 7%
1.2%
16
eLife
5422 papers in training set
Top 49%
1.2%
17
iScience
1063 papers in training set
Top 23%
1.1%
18
Cell Stem Cell
57 papers in training set
Top 2%
1.0%
19
ACS Nano
99 papers in training set
Top 3%
1.0%
20
Nature
575 papers in training set
Top 13%
1.0%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.0%
22
PLOS Pathogens
721 papers in training set
Top 7%
1.0%
23
Angewandte Chemie International Edition
81 papers in training set
Top 3%
0.9%
24
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.5%
0.8%
25
Theranostics
33 papers in training set
Top 1%
0.7%
26
Cell Reports Methods
141 papers in training set
Top 5%
0.7%
27
Cell Chemical Biology
81 papers in training set
Top 3%
0.7%
28
JCI Insight
241 papers in training set
Top 7%
0.7%
29
ACS Synthetic Biology
256 papers in training set
Top 3%
0.6%
30
Brain
154 papers in training set
Top 5%
0.6%